Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 8 for:    budesonide | Covid19

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04278404
Recruitment Status : Recruiting
First Posted : February 20, 2020
Last Update Posted : October 14, 2020
Sponsor:
Collaborators:
The Emmes Company, LLC
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Duke University

Brief Summary:
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

Condition or disease Intervention/treatment
Coronavirus Infection (COVID-19) Pulmonary Arterial Hypertension Urinary Tract Infections in Children Hypertension Pain Hyperphosphatemia Primary Hyperaldosteronism Edema Hypokalemia Heart Failure Hemophilia Menorrhagia Insomnia Pneumonia Skin Infection Arrythmia Asthma in Children Bronchopulmonary Dysplasia Adrenal Insufficiency Fibrinolysis; Hemorrhage Attention Deficit Hyperactivity Disorder Multisystem Inflammatory Syndrome in Children (MIS-C) Kawasaki Disease Coagulation Disorder Down Syndrome Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:

Layout table for study information
Study Type : Observational
Estimated Enrollment : 5000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs
Actual Study Start Date : March 5, 2020
Estimated Primary Completion Date : April 24, 2024
Estimated Study Completion Date : April 24, 2024


Group/Cohort Intervention/treatment
Children and young adults who are prescribed drugs of interest
Children and young adults who are prescribed drugs of interest as part of their routine medical care OR are SARS-CoV-2 positive.
Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
Other Names:
  • Aminocaproic acid
  • Amiodarone
  • Bosentan
  • Budesonide
  • Cefdinir
  • Cefepime
  • Ceftazidime
  • Clindamycin
  • Clobazam
  • Dexamethasone
  • Dexmedetomidine
  • Dextroamphetamine/Amphetamine
  • Fosfomycin
  • Furosemide
  • Gabapentin
  • Guanfacine
  • Hydrocortisone
  • Labetalol
  • Meropenem
  • Metformin
  • Milrinone
  • Nalbuphine
  • Nicardipine
  • Nifedipine
  • Oseltamivir
  • Oxycodone
  • Risperidone
  • Sertraline
  • Sevelamer Carbonate / Sevelamer Hydrochloride
  • Spironolactone
  • Terbutaline
  • Tranexamic acid
  • Voriconazole
  • Zolpidem
  • Azithromycin
  • Lopinavir/Ritonavir
  • Ribavirin
  • Tocilizumab
  • Anakinra
  • Aspirin
  • Canakinumab
  • Colchicine
  • Interferon
  • Remdesivir
  • Ruxolitinib
  • Sarilumab




Primary Outcome Measures :
  1. Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling [ Time Frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days. ]
  2. Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling [ Time Frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days. ]
  3. Elimination rate constant (ke) as measured by PK sampling [ Time Frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days. ]
  4. Half-life (t1/2) as measured by PK sampling [ Time Frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days. ]
  5. Absorption rate constant (ka) as measured by PK sampling [ Time Frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days. ]
  6. AUC (area under the curve) as measured by PK sampling [ Time Frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days. ]
  7. Maximum concentration (Cmax) as measured by PK sampling [ Time Frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days. ]
  8. Time to achieve maximum concentration (Tmax) as measured by PK sampling [ Time Frame: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days. ]

Biospecimen Retention:   Samples With DNA
Whole blood, effluent samples, and plasma.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Children under 21 years of age.
Criteria

Inclusion Criteria:

  1. Participant is < 21 years of age and

    1. is receiving understudied drugs of interest (DOIs) per standard of care (SOC) as prescribed by their treating provider OR
    2. is NOT receiving one or more of the study drugs of interest but is SARS-CoV-2 positive within 60 days prior to enrollment

      2. Parent/ Legal Guardian/ Adult Participant can understand the consent process and is willing to provide informed consent/HIPAA

      Exclusion Criteria:

      1. Participant has a known pregnancy

        For participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling:

        (Refer to DOI specific appendices for details on enrollment cohort specifications)

      2. Has had intermittent dialysis within previous 24 hours
      3. Has had a kidney transplant within previous 30 days
      4. Has had a liver transplant within previous 1 year
      5. Has had a stem cell transplant within previous 1 year
      6. Has had therapeutic hypothermia within previous 24 hours
      7. Has had plasmapheresis within the previous 24 hours
      8. Has a Ventricular Assist Device
      9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04278404


Contacts
Layout table for location contacts
Contact: Chi Hornik (919) 260-7626 chi.hornik@duke.edu
Contact: Jerry Kirchner (919) 812-1798 jerry.kirchner@duke.edu

Locations
Show Show 49 study locations
Sponsors and Collaborators
Duke University
The Emmes Company, LLC
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
Layout table for investigator information
Principal Investigator: Chi Hornik Duke Clinical Research Institute
Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT04278404    
Other Study ID Numbers: Pro00103838
First Posted: February 20, 2020    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Budesonide
Infection
Communicable Diseases
Urinary Tract Infections
Coronavirus Infections
Severe Acute Respiratory Syndrome
Bronchopulmonary Dysplasia
Down Syndrome
Menorrhagia
Hypertension
Hemostatic Disorders
Mucocutaneous Lymph Node Syndrome
Blood Coagulation Disorders
Hyperphosphatemia
Hypokalemia
Adrenal Insufficiency
Hyperaldosteronism
Disease
Syndrome
Hemorrhage
Attention Deficit Disorder with Hyperactivity
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Nervous System Diseases
Mental Disorders
Attention Deficit and Disruptive Behavior Disorders